BRAF (Fig. 1), a component of MAPK signaling pathway, has a mutation rate of 8–12% in CRC metastasis, of which more than 90% was derived from V600E [4, 5, 111, 122]. This evidence concerns the gene BRAF and colorectal carcinoma.